The Plecanatide Chronic Idiopathic Constipation (CIC) Study
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose
ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to
placebo in patients with Chronic Idiopathic Constipation (CIC).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc. Synergy Pharmaceuticals Inc.